X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs STRIDES SHASUN LTD - Comparison Results

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA STRIDES SHASUN LTD AJANTA PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 28.5 15.2 187.4% View Chart
P/BV x 11.8 1.8 666.8% View Chart
Dividend Yield % 0.5 0.6 90.9%  

Financials

 AJANTA PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
STRIDES SHASUN LTD
Mar-17
AJANTA PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,7201,275 134.9%   
Low Rs1,103918 120.2%   
Sales per share (Unadj.) Rs194.6389.6 50.0%  
Earnings per share (Unadj.) Rs45.228.0 161.7%  
Cash flow per share (Unadj.) Rs50.348.9 102.9%  
Dividends per share (Unadj.) Rs8.004.50 177.8%  
Dividend yield (eoy) %0.60.4 138.1%  
Book value per share (Unadj.) Rs132.0303.1 43.6%  
Shares outstanding (eoy) m88.7789.42 99.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.32.8 257.7%   
Avg P/E ratio x31.239.2 79.6%  
P/CF ratio (eoy) x28.122.4 125.2%  
Price / Book Value ratio x10.73.6 295.6%  
Dividend payout %17.716.1 110.0%   
Avg Mkt Cap Rs m125,29998,036 127.8%   
No. of employees `000NA5.8 0.0%   
Total wages/salary Rs m2,5705,881 43.7%   
Avg. sales/employee Rs ThNM6,005.9-  
Avg. wages/employee Rs ThNM1,014.0-  
Avg. net profit/employee Rs ThNM431.2-  
INCOME DATA
Net Sales Rs m17,27534,834 49.6%  
Other income Rs m1661,686 9.9%   
Total revenues Rs m17,44236,520 47.8%   
Gross profit Rs m5,8076,428 90.3%  
Depreciation Rs m4511,872 24.1%   
Interest Rs m492,269 2.2%   
Profit before tax Rs m5,4743,973 137.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m1,460470 310.6%   
Profit after tax Rs m4,0142,501 160.5%  
Gross profit margin %33.618.5 182.2%  
Effective tax rate %26.711.8 225.4%   
Net profit margin %23.27.2 323.6%  
BALANCE SHEET DATA
Current assets Rs m7,63938,165 20.0%   
Current liabilities Rs m2,71530,402 8.9%   
Net working cap to sales %28.522.3 127.9%  
Current ratio x2.81.3 224.1%  
Inventory Days Days4377 55.9%  
Debtors Days Days79104 75.3%  
Net fixed assets Rs m6,91437,639 18.4%   
Share capital Rs m177894 19.8%   
"Free" reserves Rs m11,44226,210 43.7%   
Net worth Rs m11,72127,105 43.2%   
Long term debt Rs m14916,377 0.9%   
Total assets Rs m14,81481,168 18.3%  
Interest coverage x112.92.8 4,105.9%   
Debt to equity ratio x00.6 2.1%  
Sales to assets ratio x1.20.4 271.7%   
Return on assets %27.45.9 466.7%  
Return on equity %34.29.2 371.2%  
Return on capital %46.512.1 386.1%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,42213,465 77.4%   
Fx outflow Rs m1,6784,076 41.2%   
Net fx Rs m8,7449,389 93.1%   
CASH FLOW
From Operations Rs m3,2642,881 113.3%  
From Investments Rs m-2,093-7,051 29.7%  
From Financial Activity Rs m-1,1863,382 -35.1%  
Net Cashflow Rs m-15-788 1.9%  

Share Holding

Indian Promoters % 73.8 27.7 266.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 37.8 4.1%  
FIIs % 7.6 8.6 88.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 25.9 65.6%  
Shareholders   20,968 56,241 37.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  WOCKHARDT LTD.  NOVARTIS  DR. DATSONS LABS  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Idea Plunges 5% on Weak Q3 Peformance(Closing)

Indian share markets finished on a flat note after a five-session record-setting spree as profit booking was witnessed in metal stocks, capital goods stocks.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 24, 2018 03:33 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS